Omeza Appoints Vice President and Chief Commercial Officer

Omeza appointed Santino Costanzo as Vice President and Chief Commercial Office. With over 35 years’ experience in medical sales leadership, he will develop, direct and scale Omeza’s sales and marketing teams to meet strategic commercial objectives.

Founder and CEO Tom Gardner said, “Omeza is aiming to achieve market leadership by providing safe and effective omega-3 rich wound healing products, priced reasonably, and so simple to deliver that providers can apply at any site of care. Having a chief commercial officer with Santino’s extensive experience to guide our launch, and develop and lead our commercialization team long-term, leaves me feeling confident that the kind of outcomes patients and payers are seeking is finally close at hand.”

In September, Omeza received 510(k) approval of its lead drug-device combination product, Omeza® Collagen Matrix, and FDA clearance to go to market.

States Santino, “I come to Omeza to develop it into a top-tier company that keeps focused on the patients, clinicians, and various sites of care. Having seen the advantages and efficacy of its products, and met the people behind them, I see an opportunity to develop a highly skilled field force. There are many patients in the primary care setting that Omeza can and will help.”

Since 2015, Santino served as director of national accounts at Organogenesis Inc., recruited back to increase sales performance and position with the company’s national accounts. Organogenesis is currently a global leader in advanced wound care.

Previously, he was vice president of sales with start-up Amniox Medical, which serves the orthopedic and wound care markets with regenerative tissue products. Prior to that, he contracted as vice president of sales to wound care start-up Harbor MedTech, and as area vice president of sales to wound care start-up Spiracur.

Santino was vice president of sales and marketing for Organogenesis from 2003 through 2011, developing the company’s commercialization programs after the lab emerged from bankruptcy.

Earlier, he was national sales director for tissue engineering at Novartis Pharmaceuticals, created in 1996 through a merger of Ciba-Geigy and Sandoz. Prior to that, he was a regional account manager with Sandoz Pharmaceuticals. He earned his B.S. in Business Administration from Robert Morris University.